【摘要】 评价吉西他滨单药以及联合白蛋白结合型紫杉醇(Nab-P)治疗局部晚期或转移性胰腺癌的疗效、临床受益反应、生存时间及不良反应。回顾分析2012年9月~2015年9月我院收治的晚期胰腺癌患者53例,随机分为吉西他滨单药组(23例)和吉西他滨+Nab-P组(30例);单药组:吉西他滨1 000 mg/m~2、第1天、第8天,静脉滴注30 min,每隔3周重复,连续6周,联合用药组:吉西他滨用法同单药组,Nab-P 125 mg/m~2第1天、第8天,静脉滴注,每隔3周重复,连续6周。53例患者均可评价其客观有效率,可评价其临床收益反应者43例(单药组19例;联合用药组24例):单药组及联合用药组有效率分别为21.7%和33.3%(p<0.05);临床收益率分别为77.1%和61.2%(p>0.05),两组6个月的生存率分别为61.7%和70.2%(p>0.05),1年生存率分别为29.7%、33.1%(p>0.05);中位无疾病进展期分别为3.9个月和5.9个月(p>0.05),中位总生存时间分别为6.9个月和9.3个月(p>0.05),两组不良反应的差别均无统计学意义(p>0.05)。吉西他滨联合白蛋白结合紫杉醇能够安全有效地治疗晚期胰腺癌,前者效率要优于后者,并且在延长生存期方面也显示出一定的优势,但该差异无明显统计学意义。更多还原

【Abstract】 The response rate(RR), clinical benefit response(CBR), survival time and toxicity of gemcitabine and gemcitabine plus Nab-P were evaluated with the treatment of locally advanced or metastatic cancer. Fifty-three advanced pancreatic cancer patients were collected from September 2012 to 2015 in Huaihe hospital. All patients were divided in two groups randomly, control group: gemcitabine(23 cases) and treatment group: gemcitabine plus Nab-P(30 cases). In control group, patients were given gemcitabine 1 000 mg/m~2 on the 1stand 8thday with intravenou drip 30 min, and repeated every 3 weeks for consecutive 6 weeks. In treatment group, patients were given gemcitabine(usage as well as control group) and Nab-P 125 mg/m~2 on the 1stand 8thday, with intravenou drip 30 min,and repeated every 3 weeks for consecutive 6 weeks. All patients were available for objective response and fourty-three(19 cases in control groups and 24 cases in treatment groups) patients were suitable for CBR evaluation.In control group and treatment group, RRs were 21.7% and 33.3%(p<0.05); CBRs were 77.1% and 61.2%(p>0.05);the 6 month surival rates were 61.7% and 70.2%(p>0.05); the 12-month survival rates were 29.7% and 33.1%(p>0.05) respectively; the progression-free survivals(PFS) were 3.9 months and 5.5 months(p>0.05), and the median overall survivals were 6.9 months and 9.3 months, the incidence of toxicity between the two groups was not significant difference(p>0.05). The two kinds of chemotherapy regiments were effective and safe for treating locally advanced or metasetatic pancreatic cancer. Gemcitabine plus Nab-P was better than gemcitabine in RR, and had superiority in survival rates, but there was no significant difference between two chemotherapy regiment.更多还原